Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bladder replacement versus urinary diversion? A well thought answer]

J Castiñeiras, J E Camacho

    Actas Urologicas Espanolas
    |June 1, 1996
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Diagnosis and treatment for clinically localized prostate cancer. Adherence to the European Association of Urology clinical guidelines in a nationwide population-based study - GESCAP group.

    Actas urologicas espanolas·2017
    Same author

    WITHDRAWN: Management and follow-up of the male with Lower Urinary Tract Symptoms secondary to Benign Prostate Hyperplasia.

    Actas urologicas espanolas·2016
    Same author

    Involvement of HLA class I molecules in the immune escape of urologic tumors.

    Actas urologicas espanolas·2013
    Same author

    [Referral criteria for benign prostatic hyperplasia in primary care: the 2011 update. Comité Científico de Criterios de Derivación en Hiperplasia Benigna de Próstata].

    Actas urologicas espanolas·2012
    Same author

    Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation.

    European urology·2004
    Same author

    Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer.

    BJU international·2002